Safe Model of HIV Infection to Assess Antiretroviral Activity of Medical Drugs

The aim of the investigation is to develop the safe model of HIV infection to assess the efficacy of antiretroviral drugs.

Materials and Methods. The HIV infection model was designed on the basis of human cell culture and recombinant lentivirus carrying the gene of green fluorescent protein (gfp). Recombinant lentivirus has the structure of 1 type HIV (HIV-1) from which genomic RNA was removed from using genetic engineering method. Cell provirus integration was assessed by gfp gene expression. By means of the model the activity of known medical drugs used for HIV infection treatment was determined.

Results. The model simulates three stages of HIV-1 cycle: reverse transcription, pre-integration complex formation and its delivery to the nucleus, provirus integration into cell genome. Nucleoside (Zidovudine and Lamivudine) and non-nucleoside (Efavirenz) inhibitors of reverse transcriptase effecting at the stage of HIV reverse transcription, significantly suppressed provirus integration into human cell genome, while fusion inhibitor (Enfuvirtide) and HIV protease inhibitor (Atazanavir) did not have such an effect as they act only at later stages not represented in the model.

Conclusion. The suggested model can be used not only for pharmaceuticals testing but also for screening new modalities of having an effect on human cells including gene therapy.

1. Pokrovskiy V.V., Ermak T.L., Belyaeva V.L., Yurin O.G. VICh-infektsiya, klinika, diagnostika, lechenie [HIV infection, clinical picture, diagnostics, treatment]. Moscow: GEOTAR-Meditsina; 2000; 204 p.
2. Wainberg M.A., Jeang K.-T. 25 years of HIV-1 research — progress and perspectives. BMC Medicine 2008; 6: 31.
3. Bailey A.C., Fisher M. Current use of antiretroviral treatment. Br Med Bull 2008; 87: 175–192.
4. Basavapathruni A., Anderson K.S. Reverse transcription of the HIV-1 pandemic. FASEB J 2007 Dec; 21(14): 3795–3808.
5. Clair M.St., Pennington K.N., Rooney J., Barry D.W. Rapid screening of antiretroviral combinations. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995; 10 (Suppl. 1): 524–527.
6. Dias A.S.P., Bester M.J., Britz R. F., Apostolides Z. Animal models used for the evaluation of antiretroviral therapies. Current HIV Research 2006; 4: 431–446.
7. Naldini L., Blomer U., Gallay P. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272(5259): 263–267.
8. Anokhin V.A., Golovin E.V., Rizvanov A.A. Infektsionnye bolezni 2009; 6(4): 46–50.
9. Registr lekarstvennykh sredstv Rossii. Spravochnik [Russian pharmaceutical products register. Guide]. RLS®. Moscow: Meditsina; 2008; 1214 p.
10. Lekarstvennye preparaty v Rossii. Spravochnik Vidal’ [Pharmaceutical drugs in Russia. Vidal Guide]. Moscow: AstraFarmServis; 2009; 1448 p.
11. Rafal’skiy V.V. Farmateka 2008; 4: 1–8.
12. Doyle A., Griffiths J.B., editors. Cell and tissue culture: laboratory procedures in biotechnology. West Sussex, UK: John Wiley & Sons, Ltd; 1998.
13. Barde I., Zanta-Boussif M.A., Paisant S., Leboeuf M., Rameau P., Delenda C., Danos O. Efficient control of gene expression in the hematopoietic system using a single Tet-on inducible lentiviral vector. Molecular Therapy 2006; 13(2): 382–390.
14. Schambach A., Swaney W.P., van der Loo J.C.M. Chapter 14. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. In: Baum C. (editor). Genetic Modification of Hematopoietic Stem Cells: Methods and Protocols. New York: Humana Press, a part of Springer Science + Business Media, LLC; 2009; p. 191–205.
15. Rossi J.J., June C.H., Kohn D. Genetic therapies against HIV. Nature Biotechnology 2007; 25(12): 1444–1454.

Golovin Е.V., Mustafin I.G., Martynova Е.V., Galeev О.R., Anokhin V.А., Rizvanov А.А. Safe Model of HIV Infection to Assess Antiretroviral Activity of Medical Drugs. Sovremennye tehnologii v medicine 2012; (1): 55